Ludwig Johns Hopkins Co-director Ken Kinzler gives an overview of his team’s latest work on the early detection of cancer and discusses both the opportunities and challenges of detecting cancer earlier.
Ludwig Harvard investigator Rakesh Jain discusses how the abnormal tumor vessels and matrix create a hostile microenvironment that fuels tumor progression and confers resistance to conventional and emerging cancer treatments.
Sam Gambhir, the Virginia and D. K. Ludwig Professor of Cancer Research at Stanford University School of Medicine, gives an overview of molecular imaging technologies and how they are being utilized to monitor immunotherapies in living subjects.
Ludwig Lausanne’s Johanna Joyce introduces the general features of the tumor microenvironment; discusses critical functions of tumor-promoting myeloid cells in regulating cancer progression, metastasis and therapeutic resistance; and outlines current strategies for therapeutic targeting.
Ludwig Harvard Director George Demetri discusses the next generation of pathway-targeting therapies being tested against many cancer types and how clinical trials can be designed to optimize collaboration between lab-based researchers and clinical scientists, generating new insights into cancer sensitivity and resistance to therapy.
Ludwig Scientific Director Chi Van Dang has worked to unravel how the oncogene MYC links the aberrant metabolism of cancer cells to their unchecked proliferation.
Ludwig Oxford’s Peter Ratcliffe outlines the HIF hydroxylase pathway, discusses its evolution and considers its operation in health and disease.
Ludwig MIT Director Robert Weinberg discusses his laboratory’s extensive investigation of a complex cell-biological program known as the epithelial-mesenchymal transition (EMT). In carcinomas, EMT results in the acquisition of multiple traits associated with high-grade malignancies.
Ludwig San Diego’s Bing Ren provides an overview of current large-scale efforts to uncover functional elements of the human genome using new technologies.
Ludwig Oxford alum Sebastian Nijman discusses his development of isogenic—or genetically uniform—cell lines to study how drugs interact with the variegated genetic landscape of malignant tumors, and their application to analyze drug resistance and identify surprising candidate drug targets major cancers.
Ludwig’s Benoît Van den Eynde tells the story of this discovery and its subsequent translation to develop a pair of candidate immunotherapies, one of which will soon enter clinical trials in partnership with Pfizer.
Ludwig Stanford Director Irv Weissman covers his laboratory’s investigation of cancer stem cells with an emphasis on CD47.
Web Cavenee (a cancer geneticist), Frank Furnari (a cancer biologist) and Paul Mischel (a cancer pathologist) of Ludwig San Diego describe their joint investigation of glioblastoma over the past several years.
Ludwig Johns Hopkins Co-director Bert Vogelstein speaks about what the past four decades of research has taught us about the mechanics of cancer, what genomics and molecular biology have taught us about it and how all of this information might best be exploited to address the challenges posed by cancer.
Webinar by Ludwig alum Rickard Sandberg. The comprehensive capture of all RNA species present inside a single cell has been a long-standing goal of biology.
Ludwig Melbourne alum Matthias Ernst speaks about his research on therapeutically exploiting cytokines that link inflammation to tumor progression, including insights he has gained from mouse models used to mimic gastrointestinal tumorigenesis in the presence and absence of chronic inflammation, and the potential for interleukin-11 signaling as a therapeutic target.